Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593940 · ClinicalTrials.gov registry record · Phase 3
Immune Modulators for Treating COVID-19
A Phase 3 study, sponsored by Daniel Benjamin.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,971
- Enrollment target
NCT04593940: Completed Phase 3 study, sponsored by Daniel Benjamin.
NCT04593940 is a Phase 3 study that has completed, run by Daniel Benjamin. The registered enrollment target is 1,971 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (155% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04593940, a Phase 3 study, has completed, sponsored by Daniel Benjamin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,971 participants
- Enrollment target
Study Summary
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recovery, mortality, illness severity, and hospital resource utilization. Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use at the local clinics, including remdesivir (provided). The SoC may change during the course of the study based on other research findings. Comparisons of the agents among themselves is not a research objective. The study population corresponds to moderately and severely ill patients infected with the coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already hospitalized for treatment of COVID-19 infection as well as patients being treated for COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital. Patients both in and out of the ICU are included in the study population.
Primary Outcome
Time to recovery by day 28. The number of participants who have recovered by day 28.
Interventions
- DRUG Abatacept
- DRUG Infliximab
- DRUG Remdesivir
- DRUG cenicriviroc (closed to enrollment as of 3-Sep-2021)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,971 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-03-05 |
| Phase | Phase 3 |
What the finished NCT04593940 record still lists
NCT04593940 is an interventional study that assigns participants to a tested intervention. Its 1,971 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (155% higher).
The record links to 0 conditions, and to 4 interventions - of which Abatacept is the first listed.
NCT04593940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04593940 about?
NCT04593940 is a clinical study titled "Immune Modulators for Treating COVID-19". ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents for the treatment of moderately or severely ill patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each agent with respect to speed of recove...
What is the current status of trial NCT04593940?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,971 participants. The study started on 2020-10-15. Estimated completion is 2022-03-05.
What interventions are being tested in trial NCT04593940?
The interventions under investigation include: Abatacept (DRUG), Infliximab (DRUG), Remdesivir (DRUG), cenicriviroc (closed to enrollment as of 3-Sep-2021) (DRUG).
Who is sponsoring clinical trial NCT04593940?
This trial is sponsored by Daniel Benjamin, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04593940's enrollment target sits among peer trials
1,971 107th of 2000 higher than 1,894 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI